A supernumerary  kidney is an additional kidney to the number usually present in an organism. This often develops as the result of splitting of the nephrogenic blastema, or from separate metanephric blastemas into which partially or completely reduplicated ureteral stalks enter to form separate capsulated kidneys; in some cases the separation of the reduplicated organ is incomplete (fused supernumerary kidney). Less than a hundred cases are known of one or two supernumerary kidneys. See also
Supernumerary body part

References
Luciano A. Favorito; Ana Raquel M. Morais (May–June 2012). "Evaluation of supernumerary kidney with fusion using magnetic resonance image". IBJU. 38 (3): 428–429. doi:10.1590/s1677-55382012000300018. PMID 22765860.
Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union.It is an inhibitor of vascular endothelial growth factor (VEGF). Medical uses
It is used for the treatment of wet macular degeneration and is administered as an intravitreal injection, that is, into the eye. For cancer treatment, is given intravenously in combination with the other cancer drugs 5-fluorouracil and irinotecan and the adjuvant folinic acid.On 27 August 2014, Eylea was also indicated for the treatment of people with visual impairment due to diabetic macular oedema, according to the updated summary of product characteristics. In May 2019 FDA expanded the indication for aflibercept to include all stages of diabetic retinopathy. Contraindications
Eylea is contraindicated in patients with infections or active inflammations of or near the eye, while Zaltrap has no contraindications. Adverse effects
Common adverse effects of the eye formulation include conjunctival hemorrhage, eye pain, cataract, vitreous detachment, floaters, and ocular hypertension.Zaltrap has adverse effects typical of anti-cancer drugs, such as reduced blood cell count (leukopenia, neutropenia, thrombocytopenia), gastrointestinal disorders like diarrhoea and abdominal pain, and fatigue. Another common effect is hypertension (increased blood pressure). Interactions
No interactions are described for either formulation. Mechanism of action
In wet macular degeneration, abnormal blood vessels grow in the choriocapillaris, a layer of capillaries in the eye, leading to blood and protein leakage below the macula.